Analyst Brief
Master Brief →
CIN Take:
Bullish & Bearish Analyst Opinions for Cannabis Stocks
Sell-side ratings, price targets, upside, short interest, and valuation signals across the 494-equity CIN cannabis universe: built for institutional readers.
LIVE
CIN BRIEFING · ANALYST DESK
Coverage: — ·
Buy / Hold / Sell: — ·
Avg Upside: — ·
CMHI: —
ANALYST
Wall Street Consensus
Analyst price targets, consensus ratings, and valuation multiples for cannabis equities.
SIGNALS
BULLISH
Consensus Price Targets Rising Across Sector
Average upside potential expanding as estimates revised higher
ANALYST
Coverage Initiations Accelerating
New analyst coverage signals growing institutional interest
REGULATORY
Rescheduling Upside Not Yet Priced In
Most targets exclude Schedule III catalyst scenario
BEARISH
Short Interest Elevated on Select Names
High short ratios persist despite improving fundamentals
Consensus ratings and price targets reflect aggregated Wall Street analyst coverage — not CIN editorial positions.
| Ticker | Region | Consensus | Target | Upside | P/S | P/B | EV/EBITDA | Fwd P/E | Short Ratio |
|---|---|---|---|---|---|---|---|---|---|
| AAWH | Buy (7) | -- | -- | -- | -- | -- | -- | -- | |
| ACB | Buy (10) | $4.17 | +55.6% | 0.7x | 0.5x | -- | -- | 6.6d | |
| ACRHF | Sell (10) | -- | -- | -- | -- | -- | -- | -- | |
| AFCG | Buy (9) | $8.00 | +199.6% | 23.2x | 0.3x | -- | 3.4x | 9.3d | |
| AYRWF | Hold (7) | -- | -- | -- | -- | -- | -- | -- | |
| CAN | Strong Buy (11) | $1.66 | -- | -- | -- | -- | -- | 7.2d | |
| CBSTF | Sell (9) | -- | -- | -- | -- | -- | -- | -- | |
| CGC | Buy (12) | $1.57 | +70.7% | 1.9x | 0.8x | -- | -- | 3.8d | |
| CLVR | Hold (6) | -- | -- | -- | -- | -- | -- | -- | |
| CNTMF | Buy (5) | -- | -- | -- | -- | -- | -- | -- | |
| CRBP | Strong Buy (16) | $35.30 | +300.2% | -- | 1.3x | -- | -- | 3.7d | |
| CRDL | Strong Buy (8) | $6.92 | +453.6% | -- | 8.3x | -- | -- | 6.0d | |
| CRLBF | Buy (15) | -- | -- | -- | -- | -- | -- | -- | |
| CRON | Strong Buy (9) | $3.37 | +19.1% | 6.6x | 0.9x | -- | 29.1x | 2.8d | |
| CURLF | Buy (11) | -- | -- | -- | -- | -- | -- | -- | |
| CWBHF | Buy (7) | -- | -- | -- | -- | -- | -- | -- | |
| ELLXF | Buy (5) | -- | -- | -- | -- | -- | -- | -- | |
| FFNTF | Sell (10) | -- | -- | -- | -- | -- | -- | -- | |
| FLNT | Buy (10) | $4.25 | +19.4% | 0.5x | 8.1x | -- | -- | 0.4d | |
| GLASF | Buy (11) | -- | -- | -- | -- | -- | -- | -- | |
| GNLN | Hold (6) | $3.92 | +66.8% | 0.4x | 0.0x | -- | -- | 1.4d | |
| GRWG | Buy (9) | $2.00 | +42.9% | 2.4x | 0.7x | -- | -- | 2.8d | |
| GTBIF | Buy (13) | -- | -- | -- | -- | -- | -- | -- | |
| HITI | Strong Buy (9) | $5.14 | +136.9% | 0.4x | 2.6x | 11.0x | 25.9x | 0.7d | |
| HUGE | Strong Buy (7) | $12.50 | -- | -- | -- | -- | -- | 1.1d | |
| HYFM | Hold (6) | $6.50 | -- | 0.0x | -- | -- | -- | 1.1d | |
| IIPR | Hold (11) | $66.00 | +4.8% | 25.3x | 0.9x | -- | -- | 10.1d | |
| IMCC | Buy (7) | $6.00 | -- | -- | -- | -- | -- | 0.1d | |
| INCR | Strong Buy (7) | $1.43 | +55.4% | -- | -- | -- | -- | 0.3d | |
| ITHUF | Sell (7) | -- | -- | -- | -- | -- | -- | -- | |
| JAZZ | Buy (25) | $270.63 | +6.2% | -- | -- | -- | -- | 3.9d | |
| JUSHF | Buy (11) | -- | -- | -- | -- | -- | -- | -- | |
| LIEN | Buy (8) | $11.00 | +15.1% | -- | 0.7x | -- | -- | 1.6d | |
| MAPS | Buy (8) | -- | -- | -- | -- | -- | -- | -- | |
| MRMD | Buy (9) | -- | -- | -- | -- | -- | -- | -- | |
| NLCP | Buy (9) | -- | -- | -- | -- | -- | -- | -- | |
| OGI | Strong Buy (9) | $2.14 | +127.7% | 0.7x | 0.4x | 78.8x | 15.2x | 8.3d | |
| PCLO | -- | -- | -- | 7.6x | -0.9x | -- | -- | -- | |
| QNTM | Strong Buy (7) | $12.50 | +331.0% | -- | -- | -- | -- | 1.1d | |
| REFI | Buy (11) | $16.38 | +59.0% | -- | -- | -- | -- | 7.7d | |
| ROMJF | Buy (7) | -- | -- | -- | -- | -- | -- | -- | |
| RYM | Buy (5) | -- | -- | -- | -- | -- | -- | 2.3d | |
| SHWZ | Buy (8) | -- | -- | -- | -- | -- | -- | -- | |
| SLGWF | Strong Buy (7) | -- | -- | -- | -- | -- | -- | -- | |
| SMG | Buy (11) | $73.00 | +5.8% | -- | -- | -- | -- | 5.8d | |
| SNDL | Strong Buy (8) | $4.10 | +220.3% | 0.5x | 0.4x | 56.4x | -- | 0.8d | |
| SSIC | Buy | $11.00 | -- | -- | -- | -- | -- | 1.6d | |
| TCNNF | Buy (12) | -- | -- | -- | -- | -- | -- | -- | |
| TGIFF | Sell (9) | -- | -- | -- | -- | -- | -- | -- | |
| TLLTF | Sell (9) | -- | -- | -- | -- | -- | -- | -- | |
| TLRY | Buy (17) | $8.62 | +102.3% | 0.6x | 0.3x | 34.0x | -- | 4.9d | |
| TPB | Strong Buy (9) | $125.50 | +59.8% | -- | -- | -- | -- | 6.0d | |
| TSNDF | Buy (9) | -- | -- | -- | -- | -- | -- | -- | |
| VEXTF | Buy (8) | -- | -- | -- | -- | -- | -- | -- | |
| VFF | Strong Buy (8) | $4.92 | +137.7% | 6.0x | 0.9x | -- | -- | 4.3d | |
| VREOF | Sell (9) | -- | -- | -- | -- | -- | -- | -- | |
| VRNO | Buy (13) | -- | -- | -- | -- | -- | -- | -- | |
| ZYNE | Hold (9) | -- | -- | -- | -- | -- | -- | -- |
Terminal Dashboards
Markets
Live prices & movers
494 equities · Real-time data
Charts
Technical analysis
Interactive price history
Financials
SEC filings data
Revenue · EPS · Balance sheets
Analyst
Consensus estimates
Price targets · Ratings
Deals
Capital activity
Financing · Insider transactions
Macro
Economic context
Yields · VIX · USD · Fed
Global
International markets
13 countries · Multilateral macro data
Bullish and bearish analyst opinions by ticker
CIN aggregates sell-side coverage across a 494-equity cannabis-adjacent universe. For each of the most-searched names below, we've summarised how bullish and bearish desks typically frame the equity. Live ratings, price targets, and consensus figures update on the analyst coverage board above.
Bullish and bearish analyst opinions for Turning Point Brands, Inc. (TPB)
Bullish view. Turning Point Brands' Zig-Zag core generates steady free cash flow, and analysts covering the name typically highlight the FRE ('free-cash-flow') margin resilience across tobacco-cycle downturns.
Bearish view. Skeptics focus on the declining vape and moist-snuff exposure inside its NewGen segment and periodic regulatory friction on nicotine substitutes.
Bullish and bearish analyst opinions for TerrAscend Corp. (TSNDF)
Bullish view. TerrAscend's New Jersey and Maryland footprint gives it exposure to two of the highest-margin adult-use markets in the US, and bulls point to the pending Canada-to-US uplisting optionality if federal reform advances.
Bearish view. Bears cite leverage, ongoing cash burn, and reliance on a small handful of state markets for the bulk of EBITDA.
Bullish and bearish analyst opinions for Target Corporation (TGT)
Bullish view. Target Corporation's owned-brand mix and same-day fulfillment engine are what most sell-side desks flag as the durable margin story, especially versus mass-merchant peers.
Bearish view. Downgrades typically cite discretionary softness, unresolved DEI-related boycott overhang, and shrink pressure in urban stores.
Bullish and bearish analyst opinions for The Scotts Miracle-Gro Company (SMG)
Bullish view. The Scotts Miracle-Gro core lawn-and-garden brand throws off cash while Hawthorne (cannabis-cultivation supplies) has become a call option; bulls model a return to Hawthorne growth as the US wholesale glut clears.
Bearish view. Skeptics point to elevated leverage, weather-dependent sell-through, and years of Hawthorne inventory de-stocking that has yet to fully normalize.
Bullish and bearish analyst opinions for Organigram Global Inc. (OGI)
Bullish view. Organigram Global is one of the cheapest LP names on EV/sales, and its BAT-anchored balance sheet gives it dry powder that most Canadian peers lack.
Bearish view. Bearish views focus on the crowded Canadian rec market, thin gross margins, and the lack of a US catalyst path.
Bullish and bearish analyst opinions for Greenlane Holdings, Inc. (GNLN)
Bullish view. Greenlane Holdings has strategic distribution and brand relationships across the accessories and consumption space that bulls argue are underpriced at current market cap.
Bearish view. The bearish thesis centers on going-concern risk flagged in filings, dilution history, and dependence on a still-shrinking traditional retail channel.
Bullish and bearish analyst opinions for Village Farms International, Inc. (VFF)
Bullish view. Village Farms International has one of the lowest cultivation cost bases in Canadian rec via its Delta 3 greenhouse, and the produce segment supplies a hedge cash-flow leg most pure-plays lack.
Bearish view. Bears point to Canadian price compression, tariff exposure on the produce side, and periodic FX-currency drag on reported results.
Bullish and bearish analyst opinions for High Tide Inc. (HITI)
Bullish view. High Tide Inc.'s Canna Cabana banner has consistently taken market share in Canadian bricks-and-mortar retail, and its ELITE loyalty program is a rare recurring-revenue moat in the sector.
Bearish view. Skeptics flag razor-thin store-level margins under the discount club model and limited operating leverage as new stores open.
Bullish and bearish analyst opinions for MiMedx Group, Inc. (MDXG)
Bullish view. MiMedx Group's placental-tissue portfolio has clean AATB-accredited supply and re-established a growth track record after resolving prior accounting-restatement overhangs.
Bearish view. Bearish coverage flags CMS reimbursement risk for skin substitutes and periodic pricing scrutiny.
Bullish and bearish analyst opinions for Fluent, Inc. (FLNT)
Bullish view. Fluent, Inc. is repositioning around commerce-media (retail-media networks and post-transaction ads), and bulls see a step-change in gross margin if the mix shift takes hold.
Bearish view. Bears focus on the legacy performance-marketing decline, going-concern history, and Nasdaq listing-compliance episodes.
Bullish and bearish analyst opinions for SNDL Inc. (SNDL)
Bullish view. SNDL Inc. runs the largest private-label rec retail footprint in Canada plus liquor distribution, giving it a diversified consumer-defensive cash-flow base most cannabis peers lack.
Bearish view. Bears cite Canadian brand/retail margin compression and the drag from its investments in early-stage cannabis credit vehicles.
Bullish and bearish analyst opinions for Global-E Online Ltd. (GLBE)
Bullish view. Global-E Online's cross-border ecommerce infrastructure has become the default for Shopify's international expansion, and bulls model long-duration take-rate compounding.
Bearish view. Bears point to concentration risk (Shopify + luxury), valuation, and the potential for large-merchant in-housing.
Bullish and bearish analyst opinions for Ascend Wellness Holdings, Inc. (AAWH)
Bullish view. Ascend Wellness Holdings has a concentrated East Coast MSO footprint (New Jersey, Ohio adult-use catalysts) and is one of the cleanest balance sheets in Tier-2 MSOs.
Bearish view. Bears focus on Illinois margin pressure and reliance on rate-of-change from state-level catalysts.
Bullish and bearish analyst opinions for InterCure Ltd. (INCR)
Bullish view. InterCure Ltd. is the largest medical-cannabis distributor in Israel with steady script volume, and bulls treat it as the closest thing to a regulated pharma-cannabis pure-play.
Bearish view. Bearish coverage flags concentration in one market, currency volatility, and dependence on Israeli health-fund reimbursement policy.
Bullish and bearish analyst opinions for Rubicon Organics Inc. (ROMJF)
Bullish view. Rubicon Organics Inc. runs a certified-organic Canadian premium flower operation and has posted rare positive gross-margin quarters versus a sea of loss-making LP peers.
Bearish view. Bears note the small revenue base, Canadian rec price pressure, and limited runway for further margin expansion at scale.
Bullish and bearish analyst opinions for Trulieve Cannabis Corp. (TCNNF)
Bullish view. Trulieve Cannabis Corp. dominates Florida vertical retail; bulls model asymmetric upside if Florida adult-use passes on the next ballot cycle.
Bearish view. Bears focus on Florida single-state concentration, 280E tax burden, and the ballot-initiative binary risk itself.
Bullish and bearish analyst opinions for Jushi Holdings Inc. (JUSHF)
Bullish view. Jushi Holdings Inc. is levered to Virginia and Pennsylvania adult-use conversion; the biggest East Coast catalyst set inside Tier-3 MSOs.
Bearish view. Bears cite balance-sheet stress, dependence on legislative outcomes, and thin free-cash-flow visibility.
Bullish and bearish analyst opinions for Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Bullish view. Corbus Pharmaceuticals Holdings' ADC pipeline (CRB-701 in advanced solid tumors) is the reason the equity trades where it does; bulls see meaningful re-rating on Phase I/II readouts.
Bearish view. Bears note it is a binary clinical-development story, cash-runway sensitivity, and the absence of near-term revenue.
Bullish and bearish analyst opinions for Hydrofarm Holdings Group, Inc. (HYFM)
Bullish view. Hydrofarm Holdings Group is the leading US wholesale supplier of hydroponics equipment; bulls treat the equity as a leveraged play on a return to normalized US cultivation demand.
Bearish view. Bearish views focus on inventory de-stocking cycle length, exposure to illicit-market cultivation, and gross-margin recovery timing.
Bullish and bearish analyst opinions for Cresco Labs Inc. (CL)
Bullish view. Cresco Labs Inc. runs one of the strongest branded portfolios (Cresco, High Supply) across major US markets and is a category-share leader in Illinois flower.
Bearish view. Bears focus on debt maturities, Illinois-Pennsylvania margin compression, and the delayed federal-reform tailwind.
Bullish and bearish analyst opinions for Verano Holdings (VRNOF)
Bullish view. Verano Holdings is a top-tier US MSO with market-leading positions in Florida, New Jersey, and Illinois, plus a maturing Ohio adult-use footprint. Bulls model operating-margin expansion as flagship states scale and note the brand portfolio (Zen Leaf retail, Encore concentrates, MÜV medical) drives premium price capture that peers struggle to match.
Bearish view. Bearish views cite Florida adult-use referendum uncertainty, 280E cash-tax drag that limits reinvestment capacity, and MSO multiple compression that has held the whole peer group at deep discounts to consumer-staples benchmarks.
Bullish and bearish analyst opinions for Cannabix Technologies (BLO.CN)
Bullish view. Cannabix Technologies develops breath-based cannabis and alcohol detection devices for law enforcement and workplace screening; bullish thesis models regulatory adoption of breath-testing as adult-use spreads and roadside-impairment protocols standardise.
Bearish view. Bears cite the very early commercialisation stage, competition from established forensic-testing incumbents, and reliance on device certification cycles that are slow and jurisdictional.
Bullish and bearish analyst opinions for Evogene (EVGN)
Bullish view. Evogene runs computational-biology platforms with cannabis-genomics and specialty-crop applications; bullish forecasts model licensing revenue as agricultural biotech customers adopt its ChemPass and MicroBoost platforms.
Bearish view. Bearish views focus on Evogene's history of top-line volatility, dependence on partnership timing rather than product revenue, and the small-cap Nasdaq listing that limits institutional coverage.
Bullish and bearish analyst opinions for Charlotte's Web Holdings (CWBHF)
Bullish view. Charlotte's Web is one of the best-known CBD brands in North America with strong DTC and mass-retail distribution; bulls model any FDA action on CBD as dietary supplement as a step-change catalyst for the whole category, with Charlotte's Web positioned as the brand-share leader.
Bearish view. Bears cite persistent CBD-category revenue declines, cash-flow pressure, and dependence on future FDA rulemaking that has been stalled for years without resolution.
Bullish and bearish analyst opinions for GrowGeneration (GRWG)
Bullish view. GrowGeneration is the largest specialty hydroponic and organic gardening retailer in North America with a national footprint serving licensed cultivators; bulls model earnings recovery as US cannabis reform unlocks new state programs and cultivator capex resumes.
Bearish view. Bearish views focus on the multi-year revenue contraction as commercial cultivation overbuilt in the 2020-2022 cycle, store closures, and the correlation between GRWG top line and cannabis-operator capex which remains subdued.
Bullish and bearish analyst opinions for Hemp, Inc. (HEMP)
Bullish view. Hemp, Inc. holds industrial-hemp processing assets and land positions in North Carolina; a turnaround thesis would centre on monetising infrastructure into contract processing revenue as US hemp reform matures.
Bearish view. Bears highlight the very-small-cap OTC listing profile, going-concern signals in prior filings, dilutive financing history, and thin secondary-market liquidity.
Bullish and bearish analyst opinions for Ayr Wellness (AYRWF)
Bullish view. Ayr Wellness operates verticals in Florida, Massachusetts, Pennsylvania, Ohio, and New Jersey and has been a wholesale share gainer in Massachusetts and Ohio; bulls model Florida adult-use as a step-change catalyst if the referendum passes, and Ohio as a leverageable adult-use market that scaled quickly.
Bearish view. Bearish views cite Ayr's balance-sheet leverage, near-term note maturities that require refinancing at higher rates, and the general MSO peer-group multiple compression that has affected leveraged names disproportionately.
Bullish and bearish analyst opinions for NewLake Capital Partners (NLCP)
Bullish view. NewLake Capital is a cannabis-focused net-lease REIT with a top-tier MSO tenant roster and a well-covered dividend; bulls model steady FFO growth from CPI-linked rent escalators and future acquisitions as MSO operators refinance out of higher-cost sale-leasebacks.
Bearish view. Bears focus on tenant-concentration risk (a handful of MSOs represent most rent), refinancing risk if those MSOs run into balance-sheet stress, and interest-rate sensitivity that pressures REIT valuations broadly.
Bullish and bearish analyst opinions for PharmaCielo (PCLO.V)
Bullish view. PharmaCielo's low-cost Colombian medical-cannabis cultivation is a genuine cost-of-goods advantage in a global market where European and Latin American medical demand is still ramping; bulls model steady offtake growth into GMP-regulated pharmacy channels.
Bearish view. Bearish views highlight persistent working-capital constraints, dependence on slow medical-registration cadences abroad, and a Toronto Venture listing that has struggled to attract institutional capital.
Bullish and bearish analyst opinions for Cardiol Therapeutics (CRDL)
Bullish view. Cardiol Therapeutics is a clinical-stage biotech advancing CardiolRx (cannabidiol formulation) in acute myocarditis and recurrent pericarditis; bullish forecasts hinge on Phase III trial readouts and potential accelerated-approval pathways in orphan indications.
Bearish view. Bearish views cite standard clinical-stage biotech risk: binary trial outcomes, funding needs to reach data, and the cannabinoid-formulation regulatory pathway which remains unproven at scale in cardiac indications.
Bullish and bearish analyst opinions for Curaleaf Holdings (CURLF)
Bullish view. Curaleaf is the largest publicly-traded US MSO by revenue with the broadest state footprint and strategic international CBD and medical-cannabis positions in Germany and the UK; bulls model international as a long-duration growth optionality layered on top of the US MSO business.
Bearish view. Bears focus on the historical margin compression as Curaleaf scaled, 280E cash-tax drag, execution risk on international expansion, and MSO peer-group multiple compression that has affected even the sector leader.
Bullish and bearish analyst opinions for NextCure (NXTC)
Bullish view. NextCure is a clinical-stage immuno-oncology company whose pipeline includes cannabinoid-receptor programs that have drawn interest from cannabis-adjacent investors; bulls model partnership or licensing optionality around lead cannabinoid assets.
Bearish view. Bearish views highlight standard clinical-stage biotech risk, dilution needs to fund development, and that cannabinoid receptor work is one of several therapeutic bets rather than the primary revenue path.
Bullish and bearish analyst opinions for SpringBig Holdings (INSU)
Bullish view. SpringBig is the dominant cannabis-loyalty and CRM platform for US and Canadian dispensaries with strong recurring-revenue characteristics; bulls model sticky ARR growth as operator consolidation drives per-seat expansion and international markets like Germany open.
Bearish view. Bears cite retail-cannabis contraction in oversupplied states, price sensitivity among independent operators, and the risk that vertically-integrated MSOs internalise CRM tooling.
Bullish and bearish analyst opinions for MariMed (MRMD)
Bullish view. MariMed operates a profitable multi-state MSO with strong positions in Massachusetts and Maryland and a scaling branded portfolio (Betty's Eddies edibles, Bubby's Baked, Nature's Heritage flower); bulls model Illinois vertical build-out driving the next leg of EBITDA expansion.
Bearish view. Bearish views focus on 280E cash-tax drag, historically volatile quarterly earnings, and the risk that MSO M&A leaves smaller operators at a scale disadvantage relative to Tier-1 peers.
Bullish and bearish analyst opinions for SHF Holdings (SHFS)
Bullish view. SHF Holdings (Safe Harbor Financial) operates one of the most established cannabis-banking platforms in the US and services deposit relationships across hundreds of cannabis businesses; bulls model any incremental SAFER Banking progress as a durable tailwind for fee revenue and deposit growth.
Bearish view. Bearish views cite the small-cap listing profile, concentration in a still-immature cannabis-banking niche, and the risk that federal banking reform draws large-bank competition that pressures SHF's fee economics.
Forecast and analysis by ticker
Forward-looking thesis framing for the cannabis and cannabis-adjacent tickers most searched under the "forecast and analysis" pattern. Each entry summarises the bullish operating thesis and the bearish risks that CIN Research Desk models against; live financials, estimates, and consensus figures are on each company page.
Forecast and analysis for PharmaCielo (PCLO.V)
Bullish drivers. PharmaCielo's Colombian medical-cannabis cultivation footprint is one of the lowest-cost in the world; forecast models that assume steady offtake growth into European and Latin American medical markets show a durable path to positive EBITDA.
Bearish risks. Bearish forecasts cite persistent working-capital constraints, dependence on a slow medical-registration cadence in target markets, and a listing that has struggled to attract institutional flow.
Forecast and analysis for Intercure Ltd. (INCR)
Bullish drivers. Intercure is the largest medical-cannabis operator in Israel with an EU-GMP-certified supply chain; bulls model expansion into Germany and the UK converting existing operational scale into pan-European revenue.
Bearish risks. Bears focus on Israel's price compression, exposure to a single-country regulatory regime for most current sales, and a Nasdaq listing that trades at a small-cap discount to its underlying operations.
Forecast and analysis for Rubicon Organics (RBCN.V)
Bullish drivers. Rubicon Organics runs Canada's largest certified-organic cannabis facility and holds category-leading share in premium and organic segments; forecasts anchor on continued premiumisation of the Canadian rec market.
Bearish risks. Skeptics highlight the small addressable premium tier inside a still-oversupplied Canadian market, and the operational leverage risk if volume growth slows before scale is achieved.
Forecast and analysis for Vext Science (VEXTF)
Bullish drivers. Vext Science is a tightly-run Arizona-anchored MSO with recent expansion into Ohio's adult-use market; bulls model EBITDA growth as Ohio ramps and the balance sheet stays disciplined.
Bearish risks. Bears cite concentration in Arizona (a saturated market), OTC listing that limits institutional participation, and the small-cap capital-access disadvantage relative to the Tier-1 MSOs.
Forecast and analysis for NextCure (cannabinoid program) (NXTC)
Bullish drivers. NextCure is a clinical-stage immuno-oncology company whose cannabinoid receptor pipeline has drawn interest from cannabis-adjacent investors; bullish forecasts hinge on partnership optionality around its lead cannabinoid asset.
Bearish risks. Bearish views point to standard clinical-stage biotech risks: binary trial readouts, dilution needs to fund development, and the cannabinoid pipeline being one of several therapeutic bets rather than the primary revenue path.
Forecast and analysis for MariMed Inc. (MRMD)
Bullish drivers. MariMed operates a profitable multi-state MSO with strong Massachusetts and Maryland positions and a wholesale brand portfolio (Betty's Eddies, Bubby's Baked); bulls model margin expansion as Illinois vertical build-out matures.
Bearish risks. Bears focus on 280E cash-tax drag, historically volatile earnings, and the risk that MSO M&A activity leaves smaller operators like MariMed at a scale disadvantage.
Forecast and analysis for BiOptio / Enzolytics (cannabinoid) (ENZC)
Bullish drivers. Enzolytics is developing a fully-human monoclonal-antibody platform with cannabinoid-adjacent research programs; bullish forecasts require validation of the platform through partnership or licensing.
Bearish risks. Bearish views highlight extreme early-stage risk, minimal current revenue, ongoing dilution history, and the OTC pink-sheet listing that limits price discovery.
Forecast and analysis for Sugarmade Inc (SUWN)
Bullish drivers. Sugarmade's California CBD and delivery-service subsidiaries have exposure to two of the largest cannabis markets in North America; a turnaround thesis would hinge on operational stabilisation and any listing uplift.
Bearish risks. Bears focus on going-concern language in filings, a history of dilutive financings, and the very-small-cap OTC listing that struggles to attract institutional interest.
Forecast and analysis for 4Front Ventures (FFNT.CN)
Bullish drivers. 4Front Ventures' Illinois Matteson facility is one of the largest and lowest-cost cannabis production facilities in the US; bulls model the low-cost-producer positioning translating into wholesale share as Illinois adult-use scales.
Bearish risks. Bears cite balance-sheet stress, an aggressive Illinois wholesale strategy that competes against vertically-integrated MSOs, and a Canadian listing that trades at a discount to US MSO peers.
Forecast and analysis for POSaBIT Systems (POSAF)
Bullish drivers. POSaBIT operates cannabis-payments and point-of-sale infrastructure across a fragmented US retail landscape; bulls point to the regulatory tailwind if SAFER Banking or equivalent legislation passes and payments modernisation follows.
Bearish risks. Bears highlight the operator's small revenue base, competitive pressure from larger payments incumbents that could enter cannabis post-reform, and past dilution to fund growth.
Forecast and analysis for Neutra Corp (NTRR)
Bullish drivers. Neutra Corp has diversified cannabis-adjacent product and technology holdings; any credible turnaround thesis would centre on rationalising the portfolio and demonstrating recurring revenue.
Bearish risks. Bearish views focus on the shell-company profile, thin trading, absence of institutional coverage, and the pattern of small-cap OTC issuers reliant on periodic financings.
Forecast and analysis for Innocan Pharma (cross-list) (INNPF.TA)
Bullish drivers. Innocan Pharma's LPT (Liposomal Platform Technology) cannabidiol delivery system has veterinary and human clinical programs advancing on both sides of the Atlantic; bulls model licensing and out-partnership optionality.
Bearish risks. Bears cite clinical-stage biotech risk, funding needs to progress trials, and the small-cap profile that limits liquidity relative to conventional pharmaceutical peers.
Forecast and analysis for Springbig Holdings (INSU)
Bullish drivers. SpringBig is the dominant cannabis-loyalty and CRM platform serving several thousand US and Canadian dispensaries; bulls model sticky recurring revenue and gross-margin expansion as operator consolidation drives seat growth.
Bearish risks. Bearish views focus on retail cannabis contraction in oversupplied states, price sensitivity among independent operators, and the risk that vertically-integrated MSOs internalise CRM in-house.
Forecast and analysis for Avicanna (AVCN.TO)
Bullish drivers. Avicanna focuses on evidence-based cannabinoid pharmaceutical formulations and holds a leading position in Latin American medical-cannabis distribution; bulls model international medical growth converting research investment into repeatable revenue.
Bearish risks. Bearish forecasts cite historical cash burn, dependency on future medical-registration progress, and the small-cap Canadian listing that trades on limited volume.
Forecast and analysis for C21 Investments (CXXIF)
Bullish drivers. C21 Investments runs a compact, cash-flow-positive Nevada operation anchored by the Silver State Relief brand; bulls model steady free cash generation without further dilution.
Bearish risks. Bears cite single-state concentration risk in Nevada, exposure to the Las Vegas tourism cycle, and limited catalysts to re-rate the equity absent a broader MSO recovery.
Forecast and analysis for Chicago Atlantic BDC (LIEN)
Bullish drivers. Chicago Atlantic BDC is the largest publicly-traded cannabis-lending BDC and pays a well-covered dividend from a senior-secured cannabis loan book; bulls model continued spread capture in a capital-constrained sector.
Bearish risks. Bearish views cite concentration in cannabis-operator credit (where recovery values are uncertain), interest-rate sensitivity, and the risk that MSO deleveraging reduces future lending opportunity.
Forecast and analysis for Cresco Labs (CRLBF)
Bullish drivers. Cresco Labs is a top-five US MSO with strong presence in Illinois, Pennsylvania, and Florida and category-leading branded flower (Cresco, High Supply); bulls model operating-leverage gains as adult-use programs mature in existing states.
Bearish risks. Bears focus on 280E cash-tax drag, delayed Florida adult-use vote outcomes, and MSO-wide multiple compression that has held the group at a discount to consumer-staples peers.
Forecast and analysis for Jushi Holdings (JUSHF)
Bullish drivers. Jushi is an MSO with a dominant position in Virginia's medical market plus meaningful Massachusetts and Pennsylvania footprint; bulls model Virginia adult-use as a step-change catalyst if legislation advances.
Bearish risks. Bears cite balance-sheet leverage, delayed Virginia adult-use transition, and the general MSO-multiple compression that has affected smaller Tier-2 MSOs disproportionately.
Forecast and analysis for SynBiotic SE (SBX.DE)
Bullish drivers. SynBiotic SE is one of the largest publicly-traded European cannabis-and-CBD holding companies, benefiting from Germany's April 2024 medical-cannabis reform; bulls model consolidation of German medical distribution driving revenue scale.
Bearish risks. Bears cite Germany's regulatory implementation risk (pharmacy channel, prescription friction), competition from larger EU pharma distributors entering the space, and the Frankfurt listing's limited institutional flow.
State Market Coverage
38 States · Nightly RefreshCross-reference any analyst rating with the underlying state-level demand data. Each state page carries nightly-refreshed retail sales, tax collections, licensee counts, and wholesale prices sourced directly from state regulators.
Alaska cannabis market data
regulated program
Alabama cannabis market data
regulated program
Arkansas cannabis market data
regulated program
Arizona cannabis market data
regulated program
California cannabis market data
regulated program
Colorado cannabis market data
regulated program
Connecticut cannabis market data
regulated program
District of Columbia cannabis market data
regulated program
Delaware cannabis market data
regulated program
Florida cannabis market data
regulated program
Hawaii cannabis market data
regulated program
Illinois cannabis market data
regulated program
Kentucky cannabis market data
regulated program
Louisiana cannabis market data
regulated program
Massachusetts cannabis market data
regulated program
Maryland cannabis market data
regulated program
Maine cannabis market data
regulated program
Michigan cannabis market data
regulated program
Minnesota cannabis market data
regulated program
Missouri cannabis market data
regulated program
Mississippi cannabis market data
regulated program
Montana cannabis market data
regulated program
North Dakota cannabis market data
regulated program
New Hampshire cannabis market data
regulated program
New Jersey cannabis market data
regulated program
New Mexico cannabis market data
regulated program
Nevada cannabis market data
regulated program
New York cannabis market data
regulated program
Ohio cannabis market data
regulated program
Oklahoma cannabis market data
regulated program
Oregon cannabis market data
regulated program
Pennsylvania cannabis market data
regulated program
Rhode Island cannabis market data
regulated program
South Dakota cannabis market data
regulated program
Virginia cannabis market data
regulated program
Vermont cannabis market data
regulated program
Washington cannabis market data
regulated program
West Virginia cannabis market data
regulated program